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ABSTRACT
The majority of acute myeloid leukemia (AML) patients suffer from relapse 
and the exact etiology of AML remains unclear. The aim of this study was to gain 
comprehensive insights into the activity of signaling pathways in AML. In this study, 
using a high-throughput PepChip™ Kinomics microarray system, pediatric AML samples 
were analyzed to gain insights of active signal transduction pathway. Unsupervised 
hierarchical cluster analysis separated the AML blast profiles into two clusters. These 
two clusters were independent of patient characteristics, whereas the cumulative 
incidence of relapse (CIR) was significantly higher in the patients belonging to 
cluster-2. In addition, cluster-2 samples showed to be significantly less sensitive to 
various chemotherapeutic drugs. The activated peptides in cluster-1 and cluster-2 
reflected the activity of cell cycle regulation, cell proliferation, cell differentiation, 
apoptosis, PI3K/AKT, MAPK, metabolism regulation, transcription factors and GPCRs 
signaling pathways. The difference between two clusters might be explained by the 
higher cell cycle arrest response in cluster-1 patients and higher DNA repair mechanism 
in cluster-2 patients. In conclusion, our study identifies different signaling profiles in 
pediatric AML in relation with CIR involving DNA damage response and repair. 
www.oncotarget.com                                             Oncotarget, 2019, Vol. 10, (No. 45), pp: 4679-4690
INTRODUCTION
Acute myeloid leukemia (AML) forms a spectrum 
of diseases that share clinical and pathological features. 
Improvements in chemotherapeutic regimens and 
supportive care have increased overall survival rates in 
younger patients (<15 years of age) to more than 60%, 
however, 40% ultimately relapse requiring salvage therapy 
[1, 2]. Extensive research, including genomic sequencing 
in the TCGA project, has revealed many previously 
unknown recurrent mutations and additional mechanistic 
insights such as alternations in the epigenetic status 
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during leukemogenesis. Based on these new findings 
classification has evolved from the French-American-
British system (FAB), which was driven by morphology 
and later surface markers, to the current World Health 
Organization (WHO) classification which incorporates 
the current well-defined karyotypical, mutations 
and genetic abnormalities. The WHO system, while 
prognostic in some groups, does not guide therapeutic 
recommendations [1, 3]. AML leukemogenesis and the 
regulation of leukemic cell proliferation and survival is 
the net result of all genetic, epigenetic and environmental 
factors present in the leukemic blast manifesting through 
canonical or non-canonical utilization of the existing 
signal transduction pathways in those cells. Deregulated 
protein phosphorylation by aberrant protein kinase activity 
is frequently observed in cancer, including leukemia 
[4–10]. Aberrant activity of multiple signal transduction 
pathways has been associated with a worse prognosis [11]. 
Unlike chronic myeloid leukemia (CML), where single 
treatment with BCR-ABL inhibitors has been proven very 
successful, the use of single kinase inhibitors in AML has 
not dramatically altered outcomes as in CML [12–14]. 
The failure of single kinase inhibitor therapy is likely due 
to defensive cellular adaptations that utilize alternative 
metabolic routes, or redundancy in pathways that provide 
escape mechanism [15–16]. Therefore, improved therapy 
of AML will require therapeutic agents directed against 
the perturbed pathways downstream of these events.
To address this, we recognized the need to develop 
a global map of the activation patterns going on in all of 
the signal transduction pathways within a cell. Therefore, 
we utilized a high-throughput peptide microarray array 
and investigated the peptide activation of 976 peptides 
simultaneously and quickly to generate a global map 
of pathway activation in pediatric AML. Unsupervised 
clustering clearly divided the AML samples into two 
different profiles, named cluster-1 and cluster-2 of which 
cluster-2 was strongly related to a higher cumulative 
incidence of relapse (CIR). In addition, cluster-2 samples 
showed to be significantly less sensitive to various 
chemotherapeutic drugs than cluster-1 samples. The 
identified activated peptide patterns of two clusters were 
independent of patient characteristics such as FAB, WHO 
classification with recurrent genetic abnormalities and 
mutations. GeneGO pathway analysis revealed that cell 
cycle arrest response was highly activated in cluster-1 and 
DNA repair process in cluster-2.
RESULTS
Peptide microarray profiling identified two 
clusters of pediatric AML samples 
Figure 1A outlines our approach to investigate the 
peptide microarray profiles. We hypothesized that these 
peptide microarray profiles contained detailed intracellular 
insights providing predictive signaling information. We 
performed unsupervised hierarchical clustering with 
variance 0.15 (σ/σmax) using average linkage algorithms. 
That resulted in 192/976 recorded peptides which 
significantly separated the samples into two main clusters 
(cluster-1 and cluster-2) based on gap statistics (average 
normalized expressions for each peptide in Figure 1B). 
Additionally, we tested using increased threshold (filter 
variance 0.25) and obtained 95 differentially activated 
peptides with a similar binary pattern but the CIR 
was not significantly different between the clusters 
(Supplementary Figure 2). The peptide sequences of 
the 192 peptides with their basic functions based on the 
proteins they are derived from are given in Supplementary 
Table 4. These 192 activated peptides belonged to proteins 
involved in cell cycle regulation, cell proliferation, cell 
differentiation, apoptosis, PI3K/AKT signaling, mitogen-
activated protein kinase signaling (MAPK), metabolism 
regulation, transcription factors or G-protein-coupled 
receptors (GPCRs) signaling. It can be appreciated that 
general AML associated peptides (c-Myc, FOXO3A, 
CREB, NF-ĸβ, E2F1, C/EBP-beta, EP300, CD19) were 
found to be activated in these AML samples. 
Aberrant peptide microarray profiles observed 
for two patients cluster in comparison to CD34+ 
normal bone marrow (NBM)
Furthermore, we explored our analysis to investigate 
the aberrant peptides activated of AML samples compared 
with CD34+ NBM controls using the 192 differentially 
activated peptides. Interestingly, 161 of the total 192 
activated peptides were significantly different between 
AML samples of both cluster 1 and cluster 2 versus 
CD34+ NBM controls (Supplementary Table 1). The well-
known peptides are categorized and highlighted in Figure 
1C. As expected, AML-associated peptide activation of 
c-Myc, c-Src, NFKB1 was found to be enhanced in AML 
especially in cluster-2 patients as compared with CD34+ 
NBM. Moreover, oncogene-related peptide activity of 
B-Raf, SHP-2 showed to be commonly upregulated in 
AML samples mostly in cluster-1 patients as compared 
with CD34+ NBM. Interestingly, we found increased 
peptide activation of cell cycle regulators Rb, Rb-like-1, 
CDC25B, CDC6, RAP1GAP1, RAC1, CCND1 and 
p21cip1 that showed a strong difference in absolute peptide 
activation intensities between AML as compared with 
CD34+ NBM in coexistence with a decrease in 14-3-3 eta, 
BRCA1, Chk1 and E2F1 peptide activity. As expected, 
increased AKT, MAPK related peptides ELK1, ELK3, 
JNK1 were highly activated in AML samples as compared 
with CD34+ NBM. In summary, using peptide microarray 
profiling, we showed the impaired activity of cell cycle 
regulators, PI3K and MAPK signaling pathways in AML 
samples as compared with CD34+ NBM samples. The 
detailed list of significantly upregulated and downregulated 
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protein derived peptide activation in AML samples of two 
clusters is presented in Supplementary Table 1.
In addition, we investigated the chemosensitivity 
between these two clusters to underscore the differences 
examined in the two clusters. As shown in Figure 2A–2C, 
LC 50 values are given for 10 AML samples. Cluster-2 
samples showed to be significantly less sensitive to 
mitoxantrone (median, 31-fold, Figure 2A), etoposide 
(median, 31-fold, Figure 2B) and amsacrine (median, 
104-fold, Figure 2C) than cluster-1 samples. The dose-
dependent effect of these three drugs on cell viability 
between the leukemic cells of the two clusters are shown 
in Supplementary Figure 3A–3C. Furthermore, apoptosis 
assay by annexin v and propidium iodide staining 
showed that samples of Cluster-2 were less sensitive to 
mitoxantrone (0.5 µg/ml for 48 hours treatment) than 
Cluster-1 samples (Supplementary Figure 3D).
Comparison of patient characteristics and 
outcome between two AML clusters
No correlation between individual peptide activation 
levels and clinical characteristics (e.g. age, sex, FAB 
classification, karyotypes, blast percentage, white blood 
Figure 1: Peptide microarray profiling and its relation with patient outcome. (A) The overview of study design for peptide 
microarray profiling of pediatric AML samples to identify active signaling cascade and potential druggable targets depicted in this figure. 
PepChipTM microarray data of 96 AML patients were analyzed using unsupervised hierarchical clustering. Patients characteristics were 
correlated with clusters. Provisional scheme of the activated signal transduction pathways between two clusters was analyzed by Metacore 
GenoGo software. (B) Unsupervised hierarchical clustering of the activated peptides of the array using average linkage algorithm is 
presented in this figure. The heat map graphically represents the 192 activated peptides constructed from quantile normalized peptide 
activation intensities. Patients are significantly separated into two actual clusters by gap statistics depending on the peptide activation 
intensities. The patient karyotypes are marked in the bottom of the figure. Peptide activation activity is scaled so that green represents lower 
activation and red represents higher activation. The 192 peptides names corresponding with the phosphorylation consensus sequences of 
the proteins they originated from were presented in Supplementary Table 4 (C) Bar diagram shows the significant fold differences for a 
selective group of interesting categorized peptides between the AML samples of two clusters (cluster-1 and cluster-2) and CD34+ NBM 
controls (n = 4). Proteins from which the peptide sequences are derived and the explicit peptide phosphorylation sites are indicated in the 
graph.
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cell count, red blood cell count and platelet count) with 
multiple testing corrections was observed. The patient 
karyotypes of two clusters are shown in Supplementary 
Table 2. No significant differences in patient characteristics 
(e.g. age, sex, blasts percentage, white blood cell count, 
platelet count, frequencies of relapse, death or complete 
response and sample sources of either peripheral blood 
or bone marrow) were found between the two clusters. 
The median time to complete remission between the two 
clusters (37.5 ± 5.6 days for cluster-1 vs 40.5 ± 2.5 days 
for cluster-2) was also not significantly different. Only red 
blood cell count was significantly lower in the patients in 
cluster-2 (4 × 109/L) compared to cluster-1 (5 × 109/L) 
(Table 1A). Additionally, frequencies of the recurrent 
genetic abnormalities according to WHO classification 
[17] and mutational profiles were similar between the two 
clusters (Table 1B). Only FLT3-ITD mutation frequency 
was higher in cluster-2 patients than cluster-1 although it 
was not significant. In our data set, mutated NPM1 with 
or without FLT3-ITD was not found as definite entity. 
The overall survival was also not statistically significantly 
different between the two clusters (log-rank test, Figure 
3A) whereas CIR of cluster-2 (47%) was significantly 
higher than of cluster-1 (26%) (χ2 test, Figure 3B). 
Delineation of signal transduction networks of 
two AML clusters
To understand the different signaling dynamics 
activated in the two clusters, we performed pathway 
analysis of highly activated peptides for both cluster-1 
and cluster-2 separately. Metacore GeneGO pathway 
analysis was used to identify the top ranked most 
significantly altered pathways using enrichment analysis. 
Top 20 pathways for proteins of corresponding peptides 
upregulated in both cluster-1 and cluster-2 in GeneGo 
are presented in Supplementary Table 3. Pathways 
selectively upregulated in cluster-1 were: immune 
response related signaling pathways, DNA damage 
response, cell cycle arrest, p53 dependent apoptosis and 
melanoma progression. Pathways uniquely upregulated in 
cluster-2 included: receptors mediated signaling pathways 
(specifically via IGF-1receptor, C5a receptor, Delta-type 
opioid receptor, A1 receptor, A2 receptor and G-protein 
coupled receptors), downstream of AKT signaling 
pathways, c-Kit ligand signaling pathways, apoptosis 
inhibition and DNA repair signaling pathways. The most 
interesting key difference between the pathways of the 
two clusters was related to proteins being involved in cell 
cycle arrest, cell cycle checkpoints, cell cycle transition, 
DNA repair and DNA replication. Therefore, we built a 
protein-protein interaction network using peptides that are 
involved in cell cycle regulation. 
This network analysis suggested that the cell cycle 
axis within DNA damage response was highly activated 
in cluster-1 patients as p53 and p21 peptides were intense 
on the microarray (Figure 4A). In cluster-1, it seems that 
highly phosphorylated p53 may contribute to G1/S and 
G2/M checkpoint arrest via induction of p21. Analyzing 
ATM and γ-H2AX in our array data, both peptides were 
relatively intensely activated in cluster-1 patients based 
on absolute intensities (median intensity for ATM, 264 
vs 16 and for H2AX, 98 vs 43 in cluster-1 vs cluster-2 
respectively). Phosphorylated p53 can be activated by 
DNA damage-inducible kinase, such as ATM and also by 
H2AX and promote apoptosis. In addition, higher E2F1 
phosphorylation presumably catalyzed by ATM kinase 
was found in cluster-1 and this phosphorylation may 
induce p53 phosphorylation and apoptosis in cluster-1. 
In cluster-2, higher intensities of BRCA1, 
Chk1 and Chk2 were found. BRCA1 is known to be 
phosphorylated by Chk1 and Chk2 phosphorylation. 
Highly phosphorylated BRCA1 could participate in DNA 
repair mechanism and probably facilitate higher DNA 
Figure 2: Evaluation of the chemotherapeutic drug sensitivity between AML cells of two clusters. (A–C) Differences in 
AML cell viability between AML cells of cluster-1 and cluster-2 samples for (A) mitoxantrone, (B) etoposide and (C) amsacrine. Cluster-1 
AML cells were significantly more sensitive to all chemotherapeutic drugs (p < 0.01 for mitoxantrone, p < 0.01 for etoposide and p < 0.03 
for amsacrine). The median LC50 is depicted as the horizontal solid line with interquartile range. Differences in the distribution of LC50 
values were analyzed using nonparametric Mann- Whitney U test. P < 0.05 was considered statistically significant (2-tailed test).
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Table 1: Patient characteristics
(A)
Characteristics (n = 96)
All patients 
(mean  ±  SD)/
(no/96)
Patient in Cluster-1  
(n = 39)

















BM Blast (%) (mean ± SD) 71.7 ± 20 72.6 ± 20.1 71.1 ± 20.1 0.72
PB Blast (%) (mean ± SD) 59.3 ± 25.4 59 ± 26.9 59.4 ± 24.6 0.92
WBC, ×109/L (mean ± SD) 29.9 ± 22.1 29.6 ± 23 30.1 ± 21.7 0.69
RBC, ×109/L (mean ± SD) 4.4 ± 1.4 4.9 ± 1.3 4.1 ± 1.3 0.01*
PLT, ×107/L (mean ± SD) 37.9 ± 30 37.1 ± 27.8 38.5 ± 24.6 0.51
Relapse (no/96) 36 10 26 0.03*
Death (no/96) 43 15 28 0.27
Complete response (no/96) 64 28 36 0.29
Results were considered statistically significant when p-values were <0.05. Associations between two clusters and patient 
characteristics were assessed in SPSS (Statistical Package for the Social Sciences). Mann-Whitney U test (for continuous 
variables) was used to assess the difference between the two clusters.
(B)
























• AML otherwise not specified 



















replication process of cluster-2 AML cells. In addition, it 
could be hypothesized that faster cell cycle progression 
is promoted by higher phosphorylation of Rb and lower 
E2F1 phosphorylation in cluster-2 patients. These data 
suggest that the AML samples in cluster-1 have elevated 
p53 signaling possibly leading to apoptosis while AML 
samples in cluster-2 have elevated signaling reflected in 
DNA damage tolerance and repair. 
To confirm peptide microarray results of the cell 
cycle regulatory process, western blot analyses were 
conducted for phosphorylation status and total amounts of 
JNK1, p53, p21, Chk1, Chk2 using leukemic blasts of three 
leukemic patients for each cluster (Figure 4B, 4C). It can 
be appreciated that p-JNK1, p-p53 and p-p21 were slightly 
elevated in cluster-1 compared to cluster-2 patients (non-
significant,) and p-Chk1 and p-Chk2 levels were found to 
be significantly higher in cluster-2 compared to cluster-1 
patients as expected. Furthermore, in cluster-1 patients, 
we hypothesized that activated p53 may induce apoptosis 
signals. Within the context of higher p53 activation in 
cluster-1, a tendency of higher pro-apoptotic BAX levels 
(non-significant) and significantly lower levels of anti-
apoptotic Bcl2 were found in cluster-1 patients compared 
to cluster-2 suggesting that AML cells of cluster-1 patients 
are more prone to apoptosis. 
DISCUSSION
This study has demonstrated that peptide microarray 
profiling of AML samples provides significant details 
about AML signaling and identified two clusters associated 
with DNA damage response and repair system, resulting 
in significantly different CIR. The present study shows the 
power of high throughput peptide microarrays for the first 
time in a larger number of pediatric AML patients. 
Our previous studies have shown the feasibility 
of peptide microarray technology to develop treatment 
possibilities with specific kinase inhibitors for pediatric 
brain tumor, acute lymphoblastic leukemia and subsets 
of AML patients [16, 18, 19, 20]. Although peptide 
microarray screens provide an excellent opportunity 
to simultaneously screen for phosphorylation of the 
kinome domain on a huge number of peptide substrates, 
this technique also has some known limitations. In vitro 
peptide microarray profiling may reveal phosphorylation 
of specific peptides which may not occur in vivo since 
the tertiary structure of phosphorylation sites and the 
spatiotemporal regulatory mechanisms are lost [21]. 
Therefore, concomitant protein analyses as well as 
network analyses which built pathways of intensely 
activated peptides together, attenuates this disadvantage. 
Another limitation in our study is that with the technique 
of peptide microarrays we are not yet able to use single 
cell analysis on this platform. Therefore, we were not 
able to take different AML clones into account and 
our present data focused on the comprehensive signal 
transduction pathways in whole AML cell lysates. In this 
era, each year multiple new specific kinase inhibitors are 
developed and brought to the clinical setting. Moreover, 
treatment with a single kinase inhibitor in AML has not 
been successful often due to bypass or escape routes in 
AML cells that we have shown recently by developing 
a novel combination therapy for MLL-rearranged 
AML [21]. With MEK inhibition AML cells developed 
alternative escape routes allowing survival via extreme 
induction of VEGFR-2, while the combined inhibition of 
both MEK and VEGFR-2 limited cellular recovery was 
found via decreased AKT and mTOR activity. Another 
study explained that inhibiting mutations often showed the 
lack of sensitivity in in vitro culture and organoids [22]. 
Figure 3: Comparison of patient outcome between two AML clusters. (A) Kaplan-Meier estimates for patients over time in 
months for the proportion of surviving patients (overall survival) between two clusters (non-significant, p = 0.18) and (B) Significant 
differences of cumulative incidence of relapse (CIR) is presented between the patients of two clusters (p < 0.03). 
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Therefore, it is essential to elucidate more signaling 
insights in the cancer cell. Our current peptide microarray 
profiling resulted in several observations. 
At first, this study characterized the deregulated 
signaling pathways in pediatric AML. The peptide 
microarray profiles provided a comprehensive insight into 
signaling pathways active in pediatric AML patients. As 
expected, we found activation of proteins belonging to 
cell cycle regulation, cell proliferation, cell differentiation, 
apoptosis, PI3K/AKT signaling, MAPK signaling along 
with the regulators of metabolism, transcription factors 
and GPCRs signaling regulators in pediatric AML. 
Moreover, AML-associated peptides (c-Myc, FOXO3A, 
CREB, NF-ĸβ, E2F1, C/EBP-beta, EP300, CD19) were 
found to be activated in our array. This finding underscores 
our previous observation in leukemia that CREB, NF-ĸβ, 
E2F1 and EP300 were highly phosphorylated in MLL-
rearranged AML [16]. Other studies also showed the 
activation of FOXO3A, C/EBP-beta, Btk, LKB1, CD19 in 
AML as we have seen in the present study that FOXO3A 
and LKB1 peptides were highly activated in cluster-2 
patients and C/EBP-beta, CD19, Btk were highly activated 
Figure 4: Delineation of signal transduction networks and determination of chemosensitivity of two AML clusters. 
(A) Metacore GeneGo graphic illustration of the peptides involved in cell cycle regulation between two clusters. Network analysis was 
performed using peptides involved in the cell cycle regulatory pathway. The differentially activated peptides identified from two clusters 
are represented by circles (red colored circle denoted those peptides were upregulated in cluster-1 and blue colored circle denoted those 
peptides were upregulated in cluster-2). Protein objectives are represented by various shapes and colors depending on their functional 
annotations and colors of the lines with the indication of the functional interaction with other peptides are shown in the bottom of the 
Figure. (B) Immunoblots confirmation of the peptide activation array results using leukemic blasts of three leukemic patients for each 
cluster. Immunoblots showing the variation in phosphorylation levels of JNK1, p53, p21, Chk1 and Chk2 protein and for BAX and Bcl2 
total protein between the AML patients of two clusters. (C) The quantification of the western blot analysis is presented as a bar diagram. 
Phosphorylation of JNK1, p53, p21, Chk1 and Chk2 proteins were normalized with their total protein levels. For BAX and Bcl2 protein 
levels were normalized against β-actin. *Significant differences between two individual groups were determined by using Student’s t-test, 
p < 0.05.
Oncotarget4686www.oncotarget.com
in cluster-1 patients which suggests importance of this 
approach to identify targeting therapies for individual 
patients [23–28]. To date, however, nothing is known 
about the phosphorylation activity status of GPCRs in 
AML, therefore, these receptors could be interesting 
targets for further studies in the context of leukemia. Thus, 
it can be appreciated that, for the first time we showed the 
activated signaling pathways in pediatric AML using this 
peptide microarray.
Secondly, by unsupervised hierarchical clustering, 
two clusters of AML samples were identified, without the 
knowledge of prior class definitions and independent of 
patient characteristics e.g. blast percentage, WBC counts, 
age, sex and karyotypes but related to CIR. Moreover, 
in vitro, cluster-2 samples were more resistant to 
chemotherapeutic drugs than cluster-1 samples. Dissecting 
the peptides activation by bioinformatics analyses and 
subjecting the activated peptides to pathway analysis 
yields direct insights into signaling differences into the 
two clusters. It is tempting to hypothesize that the lower 
CIR found in cluster-1 AML samples is related to some 
remaining functionality of p53 and p21 in driving the cell 
towards cell cycle arrest, followed by apoptosis as shown 
in the low Bcl2 and high BAX protein levels. Mutations 
in p53 are rare in pediatric AML (approximately 1%) and 
correlate with worse outcome [29]. Previously, we showed 
that p53 can be activated and be functional in AML 
inducing cell cycle arrest [30]. Activation of p53 is known 
to result in the induction of p21 which further results in 
Rb-mediated E2F1 inhibition to prevent cell cycling. 
Independently of p53, p21 activation itself can inhibit 
CDK2 and prevent cells from further cell proliferation. 
Although E2F1 is known as a master regulator of cell 
proliferation, there is emerging evidence that its role is 
only visible in cancer cells and not in normal cell cycling 
[31]. It is known that E2F1 activity is also regulated by 
post-translational mechanism besides its regulation by 
Rb proteins. For example, it was shown previously that, 
increased E2F1 phosphorylation may phosphorylate p53 
and induce apoptosis by increasing E2F1-half-life by 
inhibiting Rb protein [32, 33]. 
In cluster-2 samples, high BRCA1 activation 
may facilitate DNA repair mechanism as well as the 
phosphorylation of Rb. BRCA1 plays a pivotal role in 
the repair of DNA damage, especially induced following 
chemotherapy and ionizing radiation. There are only 
limited data on the role of BRCA1 activation in leukemia, 
higher BRCA1 expression was found in resistant AML 
sample [34, 35]. Phosphorylated BRCA1 is known to 
interact with different proteins e.g. the MRN complex 
(RAD50/MRE11/NBS1) and with BRCA2 and to facilitate 
repair of DNA-double strand breaks by homologous 
recombination [36]. Inactivation of Rb-protein by 
phosphorylation may promote faster cell proliferation 
of AML cells. Rb is well known by its tumor suppressor 
property, generally attributed to its ability to bind to E2F 
family members. Released E2F from their binding with 
Rb are able to facilitate transcription of cell cycle genes. 
Previous studies suggested that Rb does not only induce its 
suppressor function through a direct interaction with E2F, 
but is capable of exerting broader effects on transcriptional 
controls and chromatin structure [37, 38]. So, based on our 
results, we hypothesized that AML samples belonging to 
cluster-2 were characterized by a pattern of high BRCA1 
phosphorylation and higher Rb phosphorylation (inactive) 
that may promote more cell proliferation of cluster-2 
AML cells. The increased ability to repair DNA damage is 
reflected in an increased incidence of relapse in cluster-2 
AML samples compared to cluster-1 AML cells. 
In conclusion, this study demonstrates the feasibility 
and strength of this peptide microarray array platform 
in a large group of AML samples. Results elucidated 
deeper insights in the active signaling pathways, its 
high interconnections, as well as the essential role cell 
cycle regulation plays in the observed difference in the 
cumulative incidence of relapse. And so it is tempting to 
explore whether the use of cell cycle inhibitors focusing on 
DNA damage response and DNA repair pathways might 
be beneficial new additives to AML treatment schedules.
MATERIALS AND METHODS
Patient population, samples collection and 
processing
This study used a total of 100 primary blood or 
bone marrow samples of newly diagnosed AML patients. 
Patients were treated according to Dutch Childhood 
Oncology Group (DCOG). After obtaining written 
informed consent, primary AML samples at diagnosis 
were collected from pediatric patients in accordance with 
the declaration of Helsinki and the study was approved by 
all participating review boards. Mononuclear cells were 
separated by Lymphoprep density gradient (Nycomed, 
Oslo, Norway), and cryopreserved in liquid nitrogen 
until use. The cryopreserved leukemia cells were thawed 
rapidly at 37° C and diluted in a 6 ml volume of newborn 
calf serum, as described previously [16]. The remaining 
blast cell population contained >95% leukemia cells 
with PI staining, as shown in our previous study and is 
referred to hereafter as leukemia cells [16]. The associated 
patient characteristics and also based on FAB and WHO 
classifications are described in Table 1A and 1B.
Peptide microarray array and data analysis
The peptide microarray profiles of AML samples 
(n = 96) and CD34+ normal bone marrow (NBM) 
samples (n = 4) were determined using the PepChipTM 
Kinomics microarray system (Pepscan, Lelystad, The 
Netherlands) as described previously [39]. Briefly, the 
peptide array contains 976 different kinase peptide-
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substrates, each spotted as triplicates. The protein-derived 
peptide sequences contain phosphorylation sites that can 
be used as substrates for kinases active in the samples. 
The assay readout is the net sum of phosphorylation at 
each peptide, whether acted on by one kinase, or several 
different kinases. The patient samples (0.5 × 106 AML 
cells) were lysed in 100 μl of cell lysis buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 
1 mM MgCl2, 1 mM β-glycerophosphate, 1 mM Na3VO4, 
1 mM NaF, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1 
mM PMSF). Peptide array incubation mix was produced 
by adding 10 ml of filter-cleared activation mix (50% 
glycerol, 50 mM [γ-33P] ATP, 0.05% v/v Brij-35, 0.25 mg/
ml bovine serum albumin, [γ-33P] ATP (1000 kBq)). Next, 
the peptide array mix and sample lysate were added onto 
the chip and incubated at 37° C in a humidified stove 
for 90 min. Subsequently, the peptide chip was washed 
twice with Tris-buffered saline with Tween, twice in 2M 
NaCl, and twice in demineralized H2O and then air-dried 
at 37° C. 
The chips were exposed to a phosphoimager plate 
for 72 hours, and the density of the spots was measured 
and analyzed with array software (ScanAlyze, version 
2.50, Eisen Software). Using grid tools from ScanAlyze 
software, spot density and individual background intensities 
were analyzed. An overview of the data analysis procedure 
is provided in Supplementary Figure 1. First, background 
signal intensities were subtracted from spot intensities 
and then data were quantile normalized. A pre-filtering 
step was performed by calculating Pearson correlation 
coefficient over the triplicates. Samples were excluded 
(4/100) from the analysis when the Pearson’s Correlation 
coefficient (r2) of triplicates was below 0.6. For further 
analysis medians from the triplicates were used. Quantile 
normalized data were analyzed using Qlucore Qmics 
Explorer version 3 (Qlucore AB, Lund, Sweden). In order 
to identify differentially activated peptides and patients 
clusters, peptides with variance 0.15 (σ/σmax) were selected 
for further analysis [40, 41]. That resulted in 192/976 
recorded peptides as the lowest number of peptides making 
a difference in outcome. Subsequently, unsupervised 
hierarchical clustering analysis with average linkage 
algorithm was performed and graphical representation 
of the results of clustering was done with this software. 
The estimated number of clusters was counted by gap 
statistics [42].
Leukemic cell viability assay 
The WST-1 assay was performed to assess the 
leukemic cell viability of primary leukemic samples 
after treated with chemotherapeutic drugs as described 
previously [16]. Briefly, this assay was performed in 
sextuple according to manufacturer’s protocol (Roche). 
AML cells were seeded at a density of 0.1–1 × 105 cells 
per 100 μl/well in a 96 wells plate in RPMI medium 
supplemented with 10% fetal calf serum with and 
without chemotherapeutic drugs (range of concentration), 
mitoxantrone (0.01–10 μg/mL, Sandoz BV, The 
Netherlands), etoposide (0.01–100 μM, Pharmachemie 
BV, The Netherlands) and amsacrine (0.01–10 μg/mL, 
ProStrakan Pharma, The Netherlands). These 
concentration ranges were determined empirically to 
obtain the largest number of evaluable dose-response 
curves in AML and allowing the calculation of LC50 
values. The mitochondrial activity of AML cell was 
measured after 48 h using a microplate reader at 450 
nm (Benchmark; Bio-Rad Laboratories). Cell survival 
percentages (viability) are determined relative to non-
treated cells. 
The cell viability data is presented by calculating 
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Differences in the distribution of LC50 values were 
analyzed using nonparametric Mann-Whitney U test. 
P < 0.05 was considered statistically significant (2-tailed 
test). The difference in median LC50 values for a specific 
drug between 2 groups of patients was presented in the 
graph. 
Pathway analysis
A system biology pathway analysis tool, MetaCoreTM 
(GeneGo Inc., St Joseph, MI, USA), based on a manually 
curated database of known molecular interactions, 
pathways, and processes, was used to explore the signaling 
pathways of the 192 differentially activated peptides. 
The activated peptides of the two different clusters were 
compared to score and rank entities in pathways most 
relevant for these 192 peptides. In MetaCoreTM, the 
statistical significance (p-value) is calculated using a 
hypergeometric distribution.  Additionally, the GeneGo 
pathway analysis platform was used to generate a protein-
protein interactional network, based on evidence in 
literature [39].
Western blot
1 × 106 cells were lysed in laemmli sample buffer 
(Bio-Rad Laboratories, Veenendaal, The Netherlands). 
Proteins were separated by SDS-polyacrylamide gel 
electrophoresis, and transported to nitrocellulose 
membranes as described previously [21]. First, the 
membranes were incubated overnight with primary 
antibodies for p-JNK1, t-JNK1, p-p53, t-p21, p-Chk1, 
p-Chk2, Bcl2, BAX and β-actin (Cell Signaling), t-p53 
(BD Biosciences) and p-p21, t-Chk1, t-Chk2 (Santa 
Cruz) followed by 1 h incubation with HRP-conjugated 
secondary antibodies (DAKO Cytomation). Protein bands 
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were visualized by chemiluminescence, using ChemiDoc 
MP System (Bio-rad laboratories).
Statistics
One way ANOVA was used for multiple 
comparisons of peptide activation between AML patients 
of cluster-1 and cluster-2 and CD34+ NBM samples and 
p-values were presented with Bonferroni corrections. 
The Kaplan-Meier method was used to generate the 
survival curves between two clusters (log-rank, χ2 
test). Cumulative incidence of relapse (CIR) which is 
the measure of relapse frequency during the follow-
up time between two clusters was tested using Pearson 
Chi-Square test. Results were considered statistically 
significant when p-values were < 0.05. Associations 
between two clusters and patient characteristics were 
assessed in SPSS (Statistical Package for the Social 
Sciences). Mann-Whitney U test (for continuous 
variables) and Pearson Chi-Square test (for categorical 
variables) were used to assess the difference between the 
two clusters. 
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